Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7822858 | 1.00 | GABRA1 (0.56) | GABRA1GABRG2GABRB3TDP1MAPT | |
| SCHEMBL2394989 | 0.84 | AKR1C3 (0.43) | GABRA1GABRG2GABRB3TDP1ALDH1A1 | |
| SCHEMBL2394991 | 0.84 | AKR1C3 (0.43) | GABRA1GABRG2GABRB3TDP1ALDH1A1 | |
| SCHEMBL1745376 | 0.84 | TTR (0.53) | GABRA1GABRG2GABRB3POLBKDM4E | |
| SCHEMBL27322404 | 0.84 | AKR1C3 (0.43) | GABRA1GABRG2GABRB3TDP1MAPT | |
| SCHEMBL1745377 | 0.84 | TTR (0.53) | GABRA1GABRG2GABRB3POLBKDM4E | |
| SCHEMBL1407820 | 0.83 | GABRA1 (0.53) | GABRA1GABRG2GABRB3TDP1MAPT | |
| SCHEMBL1407819 | 0.83 | GABRA1 (0.53) | GABRA1GABRG2GABRB3TDP1MAPT | |
| SCHEMBL7880140 | 0.83 | ABL1 (0.42) | GABRA1GABRG2GABRB3TDP1MAPT | |
| SCHEMBL7880143 | 0.83 | ABL1 (0.42) | GABRA1GABRG2GABRB3TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-02-13 | — | — | US | disclosed |
| EP-4211125-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-19 | — | — | EP | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| WO-2022054987-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-03-17 | — | — | WO | disclosed |
| EP-3443959-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | Bio-Pharm Solutions Co., Ltd. (KR) | 2019-02-20 | — | — | EP | disclosed |
| EP-3079685-B1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO PHARM SOLUTIONS CO LTD (KR) | 2018-11-28 | — | — | EP | disclosed |
| EP-3079686-B1 | SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY | BIO PHARM SOLUTIONS CO LTD (KR) | 2018-10-24 | — | — | EP | disclosed |
| US-9937145-B2 | Sulfamate derivative compound for use in preventing or treating epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-04-10 | — | — | US | disclosed |
| US-9834535-B2 | Sulfamate derivative compounds for use in treating or alleviating pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| EP-2861571-B1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO LTD (KR) | 2017-05-03 | — | — | EP | disclosed |
| WO-2013187727-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-12-19 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0765351-B1 | AMIDATION OF ESTER FUNCTIONALIZED HYDROCARBON POLYMERS | EXXON CHEMICAL PATENTS INC (US) | 1999-01-13 | — | — | EP | disclosed |
| US-5627259-A | REACTION OF OLEFIN POLYMERS WITH CARBON MONOXIDE AND ALCOHOL THEN REACTION OF ESTER WITH POLYAMINE COMPOUND RELEASING ALCOHOL COMPOUND | EXXON CHEMICAL PATENTS INC. (US) | 1997-05-06 | — | — | US | disclosed |
| EP-0765351-A1 | AMIDATION OF ESTER FUNCTIONALIZED HYDROCARBON POLYMERS | EXXON CHEMICAL PATENTS INC. (US) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995035330-A1 | AMIDATION OF ESTER FUNCTIONALIZED HYDROCARBON POLYMERS | EXXON CHEMICAL PATENTS INC. (US) | 1995-12-28 | — | — | WO | disclosed |
| EP-0607344-A1 | 3,4-DIHYDRO-4-OXO-3-(PROP-2-ENYL)-1-PHTALAZINEACETIC ACIDS AND DERIVATIVES, PREPARATIONS THEREOF AND DRUGS CONTAINING SAME | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993007109-A1 | 3,4-DIHYDRO-4-OXO-3-(PROP-2-ENYL)-1-PHTALAZINEACETIC ACIDS AND DERIVATIVES, PREPARATIONS THEREOF AND DRUGS CONTAINING SAME | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1993-04-15 | — | — | WO | disclosed |
| EP-0099165-A1 | Triazole and imidazole compounds, process for their preparation and their use as fungicides and plant growth regulators, and intermediates for their synthesis | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | SLC6A4, SLC6A3, SLC6A2 | GABRA1 120/4885GABRG2 147/4885GABRB3 113/4885 |
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | SLC6A4, SLC6A3, SLC6A2 | GABRA1 120/4885GABRG2 147/4885GABRB3 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.